Study of CIK treatment for earlier-stage esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies whether CIK therapy can help people with stages I–III esophageal cancer after they finish chemotherapy. It looks at safety and possible benefits, especially in people whose body and organs are working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed esophageal cancer found on a tissue sample (biopsy).
- Your cancer is stage I, II, or III (not stage IV).
- You already finished chemotherapy.
- Your general health is fairly good (ECOG 0–1), and you’re expected to live at least 12 weeks.
- Your blood counts are in a safe range and your heart, liver, and kidneys are working well.
- Your scans show no distant spread to other organs, and you don’t have serious uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
This Phase 2 study tests a new immunotherapy drug (candonilimab/AK104) added to chemotherapy before surgery for people with locally advanced esophageal squamous cell carcinoma. It aims to shrink the cancer and improve outcomes by treating it before the operation.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This Phase 3 trial studies whether adding sintilimab (an immunotherapy medicine) after surgery improves outcomes for people with locally advanced esophageal squamous cell carcinoma. It compares sintilimab plus a chemo/RT plan versus the same chemo/RT plan without immunotherapy.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.